The study tested a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear cell renal cell carcinoma — a type of kidney cancer. After undergoing tumor-removing surgery, the patients received their personalized vaccine at Boston’s Dana-Farber Cancer Institute.
Standard treatment for these patients is surgery to remove the tumor followed by pembrolizumab (Keytruda), but two-thirds of patients face cancer recurrence, according to a news release from Dana-Farber Cancer Institute.
About three years after the vaccine administration, all patients remained cancer-free. No dose-limiting toxicities were observed, either, from the initial doses and two booster shots.
Larger clinical trials are needed to confirm the vaccine’s efficacy, the researchers said.
Nature published the phase 1 results Feb. 5.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
